awmsg logo



vildagliptin/metformin hydrochloride (Eucreas®)


Reference No. 1930

Publication date:
22/03/2013


Appraisal information

vildagliptin/metformin hydrochloride (Eucreas®) 50 mg/850 mg film-coated tablet
vildagliptin/metformin hydrochloride (Eucreas®) 50 mg/1000 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 18/03/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, vildagliptin/metformin hydrochloride (Eucreas®) cannot be endorsed for use within NHS Wales for: treatment of type 2 diabetes mellitus in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea; or treatment of type 2 diabetes mellitus as triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.